Andreas Schneeweiss
National Center for Tumor Diseases, Heidelberg · National Center for Tumor Diseases (NCT) | Heidelberg University Hospital and German Cancer Research Center · National Center for Tumor Diseases (NCT)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Schneeweiss as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:09 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05906407 · COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast CancerGerman Cancer Research Center · recruiting · Early-Stage Breast Cancer, Neoadjuvant Therapy · principal investigator
- N/ANCT05652569 · CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast CancerGerman Cancer Research Center · recruiting · Metastatic Breast Cancer · principal investigator
- Ph4NCT05452213 · Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsInstitut fuer Frauengesundheit · unknown · Breast Cancer, Breast Neoplasms, Breast Neoplasm Female · study chair
- Ph2NCT05332561 · Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)German Cancer Research Center · recruiting · Early-stage Breast Cancer · principal investigator
- Ph4NCT05036005 · Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)Institut fuer Frauengesundheit · unknown · Breast Cancer, Breast Neoplasms, Breast Cancer Female · study chair
- N/ANCT02338167 · Praegnant Breast Cancer: Early/Advanced/MetastaticUniversity Hospital Tuebingen · recruiting · Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer) · principal investigator
- Ph3NCT02125344 · A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)GBG Forschungs GmbH · completed · Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II · principal investigator
- Ph2NCT01180504 · Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian CancerUniversity Hospital Heidelberg · unknown · Ovarian Cancer, Tubal Carcinoma, Primary Peritoneal Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:09 UTC. The ranking covers the 200 most relevant of 174 PubMed records, and a shared surname and initials can bring in a namesake. All 174 on PubMed
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med · 20183,478 citationsRCR 124.7
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med · 20192,077 citationsRCR 85.1
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.N Engl J Med · 20151,670 citationsRCR 50.9
- 998 citationsRCR 41.2
- 977 citationsRCR 27.3
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Lancet Oncol · 2014783 citationsRCR 21.4
- 776 citationsRCR 21.1
- 769 citationsRCR 33.4
- 749 citationsRCR 17.1
- 643 citationsRCR 32.9